secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-064847
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan
--------------------------------------------------------------------------------

- Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.
- Aptose enters $11.1M second amended facility with Hanmi; advances capped at $2M each, 6% interest, matures May 31, 2026.
- Facility funds clinical development of Tuspetinib for AML triplet therapy.
- Arrangement agreement restated to update meeting date; board unanimously recommends shareholders vote FOR.
- Facility is a related-party transaction exempt from formal valuation/minority approval due to financial hardship.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/0001193125-26-064847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/d70162d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-064847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer